Hyponatremia is a side effect of most diuretics but the incidence from thiazides is unknown. Join host, Geoff Wall, as he evaluates a new study from Denmark evaluating hyponatremia and thiazides.
 
The GameChanger
Thiazide diuretics are considered first-line therapy but electrolyte side effects are underevaluated. A new study suggests hyponatremia is significantly more common than previously reported, especially in the elderly.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Andersson NW, Wohlfahrt J, Feenstra B, et al. Cumulative Incidence of Thiazide-Induced Hyponatremia: A Population-Based Cohort Study. Ann Intern Med. 2023 Dec 19. doi: 10.7326/M23-1989. Epub ahead of print. PMID: 38109740.

https://www.acpjournals.org/doi/abs/10.7326/M23-1989?journalCode=aim

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the use of thiazides in hypertension and their adverse effects
2. Assess the strengths and weaknesses of the Andersson et al study

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-032-H01-P
Initial release date: 1/15/2024
Expiration date: 1/15/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Sickle cell disease (SCD) is a devastating medical condition causing pain, fatigue, and early mortality. Join host, Geoff Wall, as he evaluates a new gene therapy via CRISPR that may cure SCD.
 
The GameChanger
CRISPR is a new method to develop targeted gene editing treatments. Lovo-cel is the first FDA-approved therapy and may treat sickle cell disease (SCD) - for only $2 million.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
FDA Approval. https://www.fda.gov/vaccines-blood-biologics/lyfgenia.

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss what CRISPR is and how it can be used to treat diseases
2. Describe the use of lovotibeglogene autotemcel (lovo-cel) for sickle cell disease and its safety and efficacy data

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-031-H01-P
Initial release date: 1/8/2024
Expiration date: 1/8/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Atrial fibrillation is the most common clinical arrhythmia. The newest guidelines have significant changes in diagnosis, assessment, and treatment. Join host, Geoff Wall, with guest Matt Boyd, as they evaluate the pharmacotherapy changes in the new guidelines in this two-part episode.

The GameChanger
Rate and rhythm control medications largely have the same clinical outcomes. Patients with heart failure with reduced ejection fraction should try rhythm control first. Monitoring is key for atrial fibrillation pharmacotherapy.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Guest
Mathew Boyd, PharmD
Clinical Pharmacist
Unity Point

Reference
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023 Nov 23:S0735-1097(23)06465-3. doi: 10.1016/j.jacc.2023.08.017. Epub ahead of print. PMID: 38043043.

https://www.jacc.org/doi/10.1016/j.jacc.2023.08.017

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss rate versus rhythm control in patients with atrial fibrillation
2. Develop a monitoring plan and selection of medications in rhythm control

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-030-H01-P
Initial release date: 1/5/2024
Expiration date: 1/5/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Atrial fibrillation is the most common clinical arrhythmia. The newest guidelines have significant changes in diagnosis, assessment, and treatment. Join host, Geoff Wall, as he evaluates the first half of the guidelines in this two-part episode.

The GameChanger
Different stratifying types of atrial fibrillation no longer exist. Additionally, left atrial occlusive devices are now recommended as first-line therapy for the prevention of stroke, though anticoagulants are the treatment of choice.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023 Nov 23:S0735-1097(23)06465-3. doi: 10.1016/j.jacc.2023.08.017. Epub ahead of print. PMID: 38043043.

https://www.jacc.org/doi/10.1016/j.jacc.2023.08.017

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe new definitions of atrial fibrillation and risk factors for stroke
2. Discuss mechanical prevention of stroke in high risk patients

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-401-H01-P
Initial release date: 12/25/2023
Expiration date: 12/25/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Join Ashlee as she talks with Ina, the Director of Clinical Operations at RxGenomix, about the fascinating world of pharmacogenomics. Throughout this episode, Ashlee and Ina get into the nitty-gritty of pharmacogenomic testing - a game-changer in ensuring the right medication is administered to the right patient at the right time and dose.

Listen to this episode to equip yourself with the knowledge to grasp the potential and significance of pharmacogenomics in patient care. Whether a healthcare professional or simply curious, it's time to step into the future of personalized medicine.

In this episode, the two discuss:
- Pharmacogenomics & their implications
- The role genetics play in influencing medication responses
- Integrating pharmacogenomics into routine patient care
- The future of pharmacogenomics

Dr. Ina Liko received her Doctor of Pharmacy degree at the University of Illinois at Chicago where she was initially exposed to pharmacogenomics. She then completed a clinical residency program at Monroe Clinic where her research project was focused on the implementation of pharmacogenomics. After this initial exposure to the clinical application of pharmacogenomics, she gained experience in implementing it in a larger scale by completing a fellowship in the Clinical Implementation of Pharmacogenomics at the University of Colorado where she was exposed to a systematic approach of implementing pharmacogenomics in various therapeutic classes. Dr. Liko now serves as the Director of Clinical Pharmacogenomics Operations at RxGenomix where she works collaboratively in a multidisciplinary team leading the clinical operations.

To learn more about CEimpact's By Design memberships, click here.
To learn more about the CEimpact Advanced PGx training, click here

Follow CEimpact on Social Media:
LinkedIn
Instagram

Utter the words "Artificial Intelligence" to other preceptors and pharmacy faculty, and you might get a reaction that ranges anywhere from fear and anxiety to excitement. In this insightful discussion, we explore the fundamental question of what AI is and its diverse application in shaping the landscape of pharmacy education. Guest Tim Aungst delves into the challenges surrounding student and resident access to AI tools, shedding light on the challenges and opportunities that access brings.
 
Host
Kathy Schott, PhD
Vice President, Education & Operations
CEimpact

Guest
Timothy Dy Aungst, PharmD, RPh
Associate Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences

Get CE: CLICK HERE TO CPE CREDIT FOR THE COURSE!

CPE Information
 
Learning Objectives
At the end of this course, preceptors will be able to:
1. List a primary advantage of using artificial intelligence (AI)
2. Discuss ways in which access to AI should inform teaching strategies.

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-402-H99-P
Initial release date: 12/20/2023
Expiration date: 12/20/2024
Additional CPE details can be found here.

Dr. Schott has no relevant financial relationships with ineligible companies to disclose.

Dr. Aungst reports he is a consultant for Otsuka and an advisor for Digital Therapeutics Alliance. All relevant financial relationships have been mitigated.

This program has been:
Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.

Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors.

Follow CEimpact on Social Media:
LinkedIn
Instagram

One of the oldest medications in our pharmacopeia is digoxin. It may be used for atrial fibrillation and heart failure, although not as a first-line agent. Despite this, digoxin use is on the rise. Join host, Geoff Wall, as he evaluates why more prescribers are using digoxin.

The GameChanger
No new randomized controlled trials have been published to justify the increased use of digoxin. However, when used, providers should routinely monitor digoxin levels.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Gazzaniga G, Menichelli D, Scaglione F, et al. Effect of digoxin on all-cause and cardiovascular mortality in patients with atrial fibrillation with and without heart failure: an umbrella review of systematic reviews and 12 meta-analyses. Eur J Clin Pharmacol. 2023 Apr;79(4):473-483. doi: 10.1007/s00228-023-03470-y. Epub 2023 Mar 6. PMID: 36872367; PMCID: PMC10039090.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039090/

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Apply information on the potential uses and harms of digoxin
2. Apply a strategy for monitoring digoxin in heart failure patients

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-400-H01-P
Initial release date: 12/18/2023
Expiration date: 12/18/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Join Ashlee as she talks with Jen Moulton, the president of CEimpact, about her top five takeaways from a transformative year in pharmacy education and patient care. 

Listen to this episode to reflect on, learn, and apply the biggest lessons 2023 taught us, from the every-day practices that define us to the big picture within pharmacy education that leads us. 

In this episode, the two discuss:
- The power of focus, prioritization, and efficient processes within CEimpact.
- Technology's ever-growing influence on pharmacy education.
- How building connections with clients, team members, and customers can prevent burnout and foster positivity.
- CEimpact's efforts to address pharmacy burnout.

To learn more about CEimpact's By Design memberships, click here. 

Follow CEimpact on Social Media:
LinkedIn
Instagram

Alzheimer's Disease is a progressive terminal disease. Many treatments are focused on lifestyle modification to delay diagnosis and onset. Join host, Geoff Wall, with guest Jake Galdo, as they look at a new study evaluating the association between vaccines and the development of Alzheimer's Disease.
 
The GameChanger
Postviral inflammation may play a role in the development of Alzheimer's Disease. A recent claims-based study found an association between immunization status and the development of Alzheimer's Disease.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Jake Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Managing Network Facilitator, CPESN Health Equity
CEO, Seguridad
 
Reference
Harris K, Ling Y, Bukhbinder AS, et al. The Impact of Routine Vaccinations on Alzheimer's Disease Risk in Persons 65 Years and Older: A Claims-Based Cohort Study using Propensity Score Matching. J Alzheimers Dis. 2023;95(2):703-718. doi: 10.3233/JAD-221231. PMID: 37574727; PMCID: PMC10578243.
 
Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the potential mechanisms of inflammation and viral infections with the development of Alzheimer's Disease.
2. Describe the study discussed and its application in guiding patients to receive vaccines.

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-367-H01-P
Initial release date: 12/11/2023
Expiration date: 12/11/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Exocrine enzyme dysfunction is far more common than many primary care practitioners realize. Using pancreatic enzymes can help with symptoms and vitamin absorption. Join host, Geoff Wall, as he reviews new guidelines on the appropriate use of pancreatic enzymes.
 
The GameChanger
Chronic pancreatitis is the most common cause of exocrine dysfunction in adults. All pancreatic enzymes are equally effective; however, the use of pancreatic enzymes to treat chronic pain is controversial.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Whitcomb DC, Buchner AM, Forsmark CE. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. Gastroenterology. 2023 Nov;165(5):1292-1301. doi: 10.1053/j.gastro.2023.07.007. Epub 2023 Sep 20. PMID: 37737818.

https://www.gastrojournal.org/article/S0016-5085(23)04780-7/fulltext
 
Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss common symptoms and diagnoses associated with exocrine dysfunction.
2. Describe challenges associated with the use of pancreatic enzymes.

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-366-H01-P
Initial release date: 12/4/2023
Expiration date: 12/4/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram